Average Insider

Where insiders trade, we follow

$CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Andrew J. Hirsch
CEO
110
Employees
$2.76
Current Price
$135.95M
Market Cap
52W Low$1.69
Current$2.7630.7% above low, 69.3% below high
52W High$5.17

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells11$122,486.5945,173
2 weeksBuys00--All Sells
Sells11$122,486.5945,173
1 monthBuys00--All Sells
Sells11$122,486.5945,173
2 monthsBuys00--All Sells
Sells11$122,486.5945,173
3 monthsBuys00--All Sells
Sells11$122,486.5945,173
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 12, 2026
Adams Kendra
Chief Financial Officer
Sale45,173$2.71$122,486.59View Details
1 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 5, 2026
EPS
Estimated-$0.19
ActualN/A
Revenue
Estimated$8.52M
ActualN/A
1 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.10.12